PYNGF: Teleflex Incorporated acquiring all of the issued and outstanding common shares of the Company from the shareholders in exchange for cash consideration of US$0.30203 per common share.

FINRA deleted symbol:

http://otce.finra.org/DLDeletions

PYNGF.. $0.142

Nothing new to report..

PYT.V $0.18.. In with a much better report than last quarter,, I think we are out of the woods with this one.. hank

Pyng Medical Corp. Reports Third Quarter Fiscal 2011 Results

VANCOUVER, BRITISH COLUMBIA--(Marketwire -08/23/11)- Pyng Medical Corp. (TSX-V: PYT.V - News) today announced its financial and operating results for the three months ended June 30, 2011. All amounts are in Canadian dollars unless stated otherwise.

For the third quarter 2011, the Company has realized significant sales growth resulting in total sales of $1,723,803, up 34% from the third quarter 2010. This increase was mainly attributed to the sales from U.S. military and civilian orders after the budget issue of the U.S. government was resolved. Gross margin as a percentage of sales of 65% was slightly higher than the prior year at 64% as a result of the strong sales and cost savings, despite continuing appreciation of Canadian dollar against the U.S. dollar, causing an unfavorable effect on the majority of sales dominated in U.S. dollars. Total operating expenses dropped to 53% of the sales from 72% for the same quarter last year.

The Company's net income also rose substantially to $210,555 for this quarter, equal to $0.01 per share, compared to a net loss of $92,990 or a loss of $0.01 per share one year earlier. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations were $379,344, an increase of $322,446 as compared to $56,898 reported one year ago.

For the nine months period, the total sales climbed 13% to $5,054,810 from $4,455,042 for the comparable period last year. Meanwhile, operating expenses were down 14% to $2,909,352 from $3,377,924 incurred one year ago. The strong sales and numerous initiatives on cost saving and expense reduction have collectively contributed to an increase of $757,437 in net income to $420,136 from a net loss of $337,301 reported last year.

In addition to the improving profitability, the Company continued to maintain sufficient financial liquidity to support the profit growth and product development. As of June 30, 2011, the cash balance and working capital have increased to $305,743 and $1,183,316 respectively, as compared to the amounts of $282,993 and $761,255 as at September 30, 2010.

PYNG MADE A PROFIT YAHOOOOOOOOOOO

PYNGF.pk.. $0.20..

Pyng Medical T-POD Chosen By Major UK Ambulance Service

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 21, 2011) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announced today that the T-POD(R) has been chosen by Yorkshire Ambulance Service NHS Trust, through Pyng's exclusive dealer in the UK, Lewis's Medical Supplies, as their standardized pelvic stabilization device. Yorkshire Ambulance NHS is one of 12 Ambulance Trusts in the UK. After undergoing an extensive search and trial period on available pelvic stabilization products in the market, the T-POD(R) was chosen for Yorkshire Ambulance's frontline fleet of ambulances.

"We are very pleased to represent and provide a product with such high standards as the T-POD(R)," commented Kerry Malseed, Business Development Manager for Lewis's Medical Supplies. "The ease of application and universal sizing were just some of the many qualities that made T-POD(R) stand out from its competition."

Servicing a diverse geographical area from major cities to sparsely populated rural communities, Yorkshire Ambulance attends to more traffic collisions involving major trauma than any other ambulance service in the country. " Yorkshire Ambulance Service's need for a pelvic stabilization device was unique. Servicing rural areas that are a popular with the biking fraternity, they needed a pelvic stabilization device that provided full compression across the entire width of the pelvis and a device that didn't cause much movement of the casualty when applying. The T-POD(R) provided these features and more," added Mr. Malseed.

About Yorkshire Ambulance Service NHS Trust

Yorkshire Ambulance Service NHS Trust was formed in 2006 when three former ambulance services merged. They provide 24 hour emergency and healthcare services to a population of more than five million across the county of Yorkshire. Yorkshire Ambulance covers an urban and rural area of almost 6,000 square miles of varied terrain, from isolated moors and dales to urban areas, coastline and inner cities. Their fleet includes over 500 emergency vehicles and 460 Patient Transport Service (PTS) vehicles.

About Lewis's Medical Supplies (LMS)

For over 40 years LMS has built its reputation as one of the UK's premier occupational health and emergency medical supplies businesses. From their 24,000 sq ft distribution facility on the outskirts of Manchester, they facilitate national purchasing and distribution agreements to local authority bodies and emergency services. They support the sale of their own range of medical consumables through exclusive distribution of some of the world's most innovative medical equipment to offer their customers the complete supply solution.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Claude Neunlist
Director of International Sales
+1-514-671-0225
cneunlist@pyng.com
www.pyng.com

PYNGF..$0.162 Pyng Medical Announces Release of E-MAT(TM) Emergency Medical Tourniquet-for the EMS Market

Dow Jones and Company, Inc. - Jun 10 at 09:01

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 10, 2011) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announced today the release of their tourniquet marketed for the Emergency Medical Services (EMS) Market - E-MAT(TM).

"We are very excited to be launching this product for the EMS Market at a time when new tourniquet protocols are being introduced and implemented world-wide," commented Nadine Siqueland Gaston, Vice President of Global Sales and Marketing for Pyng.

The E-MAT(TM) features a bright, EMS orange color, setting it apart from its surroundings and making it noticeable at an accident scene. "This new high- visibility color will make it easy to see that a tourniquet has been placed on a patient," added Nadine. "It is also lightweight and compact, making it an easy fit into any medical bag."

With its new color, the E-MAT(TM) contains all the same award-winning features of the original MAT(R). By providing fast and easy application, even to trapped limbs, complete blood flow occlusion is achieved in under 30 seconds. "The E- MAT(TM) offers First Responders a quick and simple solution to stop severe extremity blood loss, allowing them time to asses other injuries," added Ms. Gaston.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes,including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Nadine Gaston
VP of Global Sales and Marketing
206.226.3082
www.pyng.com

PYNGF.. $0.162..

Pyng Medical Corp.: MAT(R) Tourniquet Has Been Adopted by the Indian Military

Dow Jones and Company, Inc. - Jun 09 at 14:42

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 9, 2011) - Pyng Medical Corp. (TSX VENTURE:PYT) announced today that the Indian Military initiated a standardization process with the MAT(R) Tourniquet by purchasing 4,500 units in Pyng's second quarter through its exclusive dealer in India, vTitan Corporation Private Limited. Pyng's MAT(R) Tourniquet has been widely accepted into various defense units across India with the view to become "standard of care", and will be adopted throughout the Indian military in the coming months.

Bobby Shah, Chief Executive Officer for vTitan India commented; "We are proud to represent a company that focuses on innovation."

"Due to the strong acceptance of the MAT(R) Tourniquet, other Pyng products are now being considered by India Defense Units." Mr. Shah further added; "We see Pyng product lines becoming a standard of care in the near future in India."

About MAT(R) Tourniquet

MAT(R) Tourniquet provides fast and easy one-handed application and stops moderate to severe extremity blood loss to damaged and trapped limbs. It is the only tourniquet that meets all U.S. Department of Defense performance requirements (www.acep.org/workarea/downloadasset.aspx?id=40782). The MAT(R) is the silver award recipient for Design of the Decade from Industrial Designers Society of America.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Nadine Gaston
VP of Global Sales and Marketing
206.226.3082
www.pyng.com

PYNGF.. $0.2888 3 mo's Earnings.. Ouch

Pyng Medical Corp. Reports Second Quarter Fiscal 2011 Results

Dow Jones and Company, Inc. - May 24 at 19:31

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 24, 2011) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced its financial and operating results for the three months ended March 31, 2011. All amounts are in Canadian dollars unless stated otherwise.

The Company reported total sales of $1,289,270 for the three months ended March 31, 2011, down 18% compared with $1,578,715 for the same quarter last year, resulting from reduced orders from the U.S. military market due to the failure of the U.S. government to approve its budget. Gross margin for the quarter ended March 31, 2011 amounted to $809,803, a decrease of $265,762 from $ 1,075,565 reported a year ago. This was mainly due to the continuing appreciation of Canadian dollar against the U.S. dollar causing an unfavorable effect on the majority of sales dominated in U.S. dollars. Total operating expenses were $1,007,576, down to 78% of sales compared to $1,350,593 or 85% of sales for the same quarter last year.

The Company also reported a smaller net loss of $197,773 for this quarter, equal to a loss of $0.01 per share, compared to a net loss of $275,028 or $0.02 per share one year earlier. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations were a loss of $63,558, which remained at the same level as last year of $64,615.

For the six months period, the total sales climbed 5% to $3,331,007 compared to $3,164,399 for the comparable period last year. Meanwhile, operating expenses were cut 19% to $1,998,571 from $2,452,784 incurred one year ago. The higher sales and reduction on operating expenses lead to a net income of $209,581 compared to a net loss of $244,311 reported last year.

As of March 31, 2011, the Company had a cash balance of $708,674 and working capital of $1,276,094, representing an increase of $425,681 and $514,839 respectively, compared to the amounts as at September 30, 2010. The overall financial position improved significantly with the increase in total assets by 2% to $8,233,910 and decrease in total liabilities by 22% to $2,289,242. Strong operating results in the first quarter and the private placement financing closed in December 2010 were primary contributors to improvements seen in cash and working capital.

Full audited financial results for fiscal year ended September 30, 2010 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer
(604) 303-7964 ext. 219
www.pyng.com

PYNGF.. $0.30 Reports First Quarter Fiscal 2011 Results

Pyng Medical Corp. Reports First Quarter Fiscal 2011 Results

Dow Jones and Company, Inc. - Feb 23 at 16:14

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 23, 2011) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced its financial and operating results for the three months ended December 31, 2010. All amounts are in Canadian dollars unless stated otherwise.

The Company continued revenue growth realized in the fourth quarter of last year and reported another record quarter with strong shipments of the flagship product FAST1. Total sales of $2,041,737 were recorded for the first quarter of fiscal 2011, up 29% from $1,585,684 from the same quarter last year. Gross margin for the quarter ended December 31, 2010 amounted to $1,398,349, an increase of $265,443 from $1,132,906 reported a year ago. Gross margin as a percentage of sales decreased from 71% to 69%, which was mainly due to the continuing appreciation of Canadian dollar against the U.S. dollar (more than 93% of sales are in U.S. dollars). Total operating expenses were $990,995, down to 49% of sales compared to $1,102,189 or 69% of sales for the same quarter last year. This was primarily due to the lower labor costs, travel costs, and interest expenses incurred during the quarter.

The Company also reported net income of $407,354 for this quarter, equal to earnings of $0.03 per share diluted, compared to $30,717 or $0.003 per share diluted for the same quarter of last year. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations increased to $575,207, 27% of the sales, compared with the EBITDA of $151,835, or 10% of sales a year ago.

As of December 31, 2010, the Company had a cash balance of $1,382,457 and working capital of $1,730,028, representing an increase of $1,099,464 and $968, 773 respectively, compared to similar amounts as of September 30, 2010. Strong operating results and the private placement financing that closed in December 2010 were primary contributors to improvements seen in cash and working capital.

Full audited financial results for fiscal year ended September 30, 2010 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer
(604) 303-7964 ext. 219
www.pyng.com

PYNGF.. 02/10/11 DD Update on FASTx(R)

Pyng Medical Provides Update on FASTx(R)

Dow Jones and Company, Inc. - Feb 10 at 10:58

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 10, 2011) - Pyng Medical (TSX VENTURE:PYT) announced that it has completed a root-cause analysis on FASTx(R) in follow-up to reported insertion failures in a handful of early military training environments. From this analysis Pyng has validated that there are times where lateral motion can bend the insertion needle (stylet). This has not been observed in the unconscious patient or in cadaver validation; however it has been seen with live/conscious healthy patients in training settings. Pyng is now pursuing several options to mitigate root-cause and anticipates choosing a final solution within the next several months.

Mark Hodge, President and Chief Executive Officer for Pyng, commented; " Shortening the FASTx(R) redevelopment timeline, while at the same time bringing back an even more robust product to market, is Pyng Medical's number one priority. The company is by no means "accepting a long timeline" and will engage all necessary resources to minimize the duration of the process."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com

PYNGF.. DD 12/30/10 DD Private Placement..

Pyng Medical Announces It Has Closed a $600,000 Private Placement

Dow Jones and Company, Inc. - Dec 30 at 09:30

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 30, 2010) - Pyng Medical Corp. ("Pyng") (TSX VENTURE:PYT) announced today that all necessary regulatory and other required approvals have been obtained and on December 29, 2010 it issued, on a non-brokered private placement basis, 3,000,000 common shares at $0.20 per share for net proceeds of $600,000 to a single investor, MDR Specialty Distribution Corporation of Williamsburg, Virginia ("MDR"). MDR is a wholesale medical supplier distributor with revenues in excess of US$50,000,000 per year. One of the principals of MDR, Mr. Herbert A. Toms 3rd, was appointed to the Pyng board of directors upon closing of the placement. Mr. Toms, one of the founders of MDR, has been in the medical device supply business for over 12 years. Mr. Toms brings extensive experience and knowledge to Pyng regarding both domestic and international medical device warehousing and distribution.

There were no finder's fees payable in connection with the placement. All securities issued in connection with the placement are subject to a statutory hold period of four months plus a day from December 29, 2010, the date of issuance, in accordance with applicable securities legislation.

The proceeds of the placement will be used for general working capital and to pursue international sales opportunities.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer & Corporate Secretary
604-303-7964
604-303-7987 (FAX)
gdorin@pyng.com
www.pyng.com

PYNGF.. 12/15/10 DD Reports Fiscal 2010 Financial Results

Dow Jones and Company, Inc. - Dec 15 at 20:58

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 15, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced its financial and operating results for the year ended September 30, 2010. All amounts are in Canadian dollars unless stated otherwise.

The Company achieved strong financial results in fiscal 2010 due to the significant sales increase in the fourth quarter. Annual sales of $7,088,837 set a new record as the highest level of revenue in the Company's history and the net income before tax rose 700% to $392,415. Gross margin for the year ended September 30, 2010 amounted to $4,834,539, an increase of $493,909 from $4,340, 630 reported for fiscal 2009. The gross margin as a percentage of revenues decreased from 72% to 68%, due primarily to the strengthening Canadian dollar during the fiscal 2010. The total operating expenses of $4,442,124 dropped to 63% of sales compared to $4,403,534 or 73% of the sales for fiscal 2009 due to cost-saving measures that the Company implemented which resulted in lower legal costs, consulting fees and other operating expenses.

The Company also reported a net income after tax of $283,415 for this year, or earning of $0.02 per share, compared to a net loss of $246,904 or loss of $0.02 per share for fiscal 2009. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations increased to $1,041,438, 15% of the sales compared with the EBITDA of $395,788, or 7% of the sales for fiscal 2009.

For the fourth quarter ended September 30, 2010, the Company recorded sales of $2,633,795, which increased by $915,523 or 53% compared with $1,718,272 for the comparative quarter of fiscal year 2009. The operating expenses decreased by 16% to $1,064,256. The net income before tax rose to $620,716, up $582,187 compared with the comparative quarter of fiscal year 2009 of $38,529. The significant increase in sales largely contributed the increase in the net income before tax.

As at September 30, 2010, the Company had a cash balance of $282,993 and working capital of $761,255, representing an increase of $130,462 and $106,649 respectively, compared to the year ended September 30, 2009. The operating activities generated $995,898 in cash before any changes in working capital, up $646,229 or 185% from $349, 669 for fiscal 2009, which was primarily due to the increased sales and non-cash expenses incurred during the year.

Full audited financial results for fiscal year ended September 30, 2010 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer
(604) 303-7964
www.pyng.com

PYNGF.. 12/13/10 DD

Pyng Medical is Honored for a Life & Limb Saving Tourniquet Design

Dow Jones and Company, Inc. - Dec 13 at 14:26

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 13, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) received the silver award from Industrial Designers Society of America for its Mechanical Advantage Tourniquet (MAT(R)). The award is part of IDSA's Design of the Decade (DoD) competition and falls under the category of " Solution to a developing world social problem".

"We are honored that the MAT(R) is acknowledged as a Design of the Decade," commented Nadine Gaston, Vice President of Global Sales and Marketing for Pyng.

The MAT(R) is recognized for its speed and effectiveness, stopping blood loss in 10 seconds and is simple enough to apply one-handed.

The DoD panel awarded 12 golds, six silvers and two bronzes in 12 categories, which included, "Best sustainable design solution", "Design's contribution to business efficiency" and "Biggest contribution to brand growth".

The designs were judged on their benefit to society, benefit to business and innovation, benefit to user and responsibility, and benefit to client and visual appeal.

It clarifies the benefits of the MAT(R) Tourniquet's superior design at a time when new tourniquet protocols are being implemented world-wide", added Nadine Gaston, Vice President of Global Sales and Marketing.

The panel of judges included top design representatives from consultancies, companies and corporations, including: Chris Bangle, BMW's former director of design; Marc Greuther, chief curator, The Henry Ford; and David Butler, IDSA, vice president of global design, The Coca-Cola Co.

The MAT(R) is a past winner of the IDSA's Gold Award for Best Medical Product Design of 2006 and in 2007 a finalist for the INDEX Award for best medical product in the world.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Nadine Gaston
VP of Global Sales & Marketing
ngaston@pyng.com

PYNG.. 11/22/10 DD Record Sales for October


Pyng Medical Achieves Record Sales for October

Dow Jones & Company, Inc. - Nov 22 at 13:18

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 22, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced record sales in the month of October, 2010 for its FAST1(R) Sternal Intraosseous Device. Nadine Gaston, Pyng Vice President of Global Sales and Marketing, noted that "Almost 8,000 FAST1(R) devices were sold in October, far surpassing results in that month from previous fiscal years. The positive momentum we had developed in our record setting 4th Quarter of Fiscal Year 2010 (July, August, September) has continued into the new Fiscal Year." Ms. Gaston also remarked, "I believe Pyng's education efforts regarding the unique clinical benefits of sternal IO are beginning to have an impact, particularly in the worldwide military market."

Mark Hodge, Pyng President and Chief Executive Officer, commented, "It's extremely gratifying to see our customers respond to Pyng's recent efforts in the creation of mutually beneficial partnerships that enhance patient care. I believe that Pyng Medical is well positioned for future growth if we continue to keep our priorities focused on patients, distributors, and business plan execution."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com

PYNGF.. DD 11/16/10

PRESS RELEASE: Pyng Medical Initiates Voluntary Recall of the FASTx(TM)

Dow Jones & Company, Inc. - Nov 16 at 10:25

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2010) - Pyng Medical (TSX VENTURE:PYT) announced today that it has initiated a voluntary recall of the FASTx(TM) Sternal Intraosseous Device. Pyng received feedback regarding inconsistent performance of FASTx(TM) in several early training sessions that were conducted and, as a result, recalled the first 400 devices shipped to distributors. Pyng has discontinued shipment of future devices until it can evaluate these happenings and determine root cause.

"This voluntary recall was initiated because it is simply the right thing to do when there is any question regarding the performance of a medical device," said Mark Hodge, President and CEO of Pyng, in a statement related to the company's action. "The Pyng technical team is working rapidly to analyze these events and determine a course of action. We will ensure that the FASTx(TM) Sternal Intraosseous Device is performing as we expect it to perform and will provide ongoing updates."

The revolutionary clinical benefits available through utilization of the FAST1(R) Sternal Intraosseous Device will not be impacted by this voluntary action. During this period of FASTx(TM) evaluation, the FAST1(R) continues to ship to customers desiring the benefits of sternal IO, anatomical land marking, automatic depth control, and secure placement.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com